title: Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases.
abstract: Because of its unique position at the convergence point of the intrinsic (contact) and extrinsic (tissue factor/factor VIIa) pathways in the coagulation system, coagulation factor Xa (FXa) has been a theoretically interesting therapeutic target for antithrombotic drugs for many years. More recently, the discovery of naturally occurring FXa inhibitors, such as tick anticoagulant peptide and antistasin, has helped substantiate FXa as a desirable target by demonstrating the efficacy and potential safety advantages of FXa inhibition over conventional antithrombotic therapy. These discoveries led to the design and development of many small-molecule inhibitors of FXa, which have provided potent and selective tools for evaluating the potential role of FXa in various diseases. In addition, these advances have been instrumental in defining the biology of FXa and have aided in the discovery of specific receptors and intracellular signaling pathways for FXa that may be important in the progression of, or the response to, various diseases.
authors.affiliation: Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. Robert.Leadley@pfizer.com
authors.forename: R J
authors.initials: RJ
authors.lastname: Leadley
authors.forename: L
authors.initials: L
authors.lastname: Chi
authors.forename: A R
authors.initials: AR
authors.lastname: Porcari
mesh_terms: D000818:Animals; D002448:Cell Adhesion; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000378:metabolism / Q000473:pathology; D003546:Cysteine Endopeptidases / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D015951:Factor Xa / Q000502:physiology*; D065427:Factor Xa Inhibitors; D006083:Graft Occlusion, Vascular / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism / Q000473:pathology; D007249:Inflammation / Q000378:metabolism; D020935:MAP Kinase Signaling System; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D044464:Receptor, PAR-2; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D018179:Receptors, Thrombin / Q000378:metabolism; D018805:Sepsis / Q000378:metabolism / Q000473:pathology; D013925:Thromboplastin / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D016207:Cytokines; D065427:Factor Xa Inhibitors; D009363:Neoplasm Proteins; D010982:Platelet-Derived Growth Factor; D044464:Receptor, PAR-2; D018179:Receptors, Thrombin; D013925:Thromboplastin; D017479:Receptors, Platelet-Derived Growth Factor; D015951:Factor Xa; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant